Updated Jul 16, 2026
Popovits Kimberly J has filed 3 SEC Form 4 filings across 3 companies in the last 90 days.

Kimberly J. Popovits is a prominent executive in the biopharmaceutical industry, known for her leadership roles at Kiniksa Pharmaceuticals and Exact Sciences Corporation. She has extensive experience in the healthcare sector, particularly in developing and commercializing innovative therapies.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-22 | KARD | Kardigan, Inc. | A — Grant or award | 20.7K | $0.00 | |
| 2026-06-08 | TXG | 10x Genomics, Inc. | A — Grant or award | 8.8K | $0.00 | |
| 2026-06-02 | KNSA | Kiniksa Pharmaceuticals International, plc | M — Option exercise | 2.8K | — | |
| 2026-03-23 | EXAS | EXACT SCIENCES CORP | D — Derivative transaction | 9.7K | — | |
| 2026-03-23 | EXAS | EXACT SCIENCES CORP | D — Derivative transaction | 6.7K | — | |
| 2025-07-30 | KNSA | Kiniksa Pharmaceuticals International, plc | M — Option exercise | 64.5K | $29.90 | $1.93M |
| 2025-07-30 | KNSA | Kiniksa Pharmaceuticals International, plc | M — Option exercise | 18.8K | $15.47 | $290K |
| 2025-07-30 | KNSA | Kiniksa Pharmaceuticals International, plc | M — Option exercise | 45.7K | $10.36 | $474K |
| 2025-06-12 | EXAS | EXACT SCIENCES CORP | A — Grant or award | 10.0K | $0.00 |
Kimberly J. Popovits is a prominent executive in the biopharmaceutical industry, known for her leadership roles at Kiniksa Pharmaceuticals and Exact Sciences Corporation. She has extensive experience in the healthcare sector, particularly in developing and commercializing innovative therapies.…
3 primary Form 4 filings in the last 90 days, covering 3 companies.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Popovits Kimberly J profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.